Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1001-1011

  Gandolfi, Greta ^a   Sancisi, Valentina ^a   Piana, Simonetta ^a   Ciarrocchi, Alessia ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

BRAF; molecular marker; papillary thyroid carcinoma

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RADIOACTIVE IODINE; RAPAMYCIN; VEMURAFENIB; BRAF PROTEIN, HUMAN; GLUTAMINE; VALINE;

BRAF GENE; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DOWNSTREAM PROCESSING; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; THYROID CARCINOMA; AMINO ACID SUBSTITUTION; ANIMAL; CARCINOMA; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; THYROID TUMOR;

AMINO ACID SUBSTITUTION; ANIMALS; CARCINOMA; GLUTAMINE; HUMANS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; VALINE;

EID: 84931065402     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28976     Document Type: Review

References (111)

1. Cantewell-Dorris ER, O'Leary JJ, Sheils OM,. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10: 385-94.
2. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
3. Fecher LA, Cummings SD, Keefe MJ, et al., Toward a molecular classification of melanoma. JCO 2007; 25: 1606-20.
4. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
5. Blokx WAM, Marcory van Dijk MCRF, Ruiter DJ,. Molecular cytogenetics of cutaneous melanocytic lesions-diagnostic, prognostic and therapeutic aspects. Hystopathology 2010; 56: 121-32.
6. Yokota T,. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-Cancer Agents Med Chem 2012; 12: 163-71.
7. Fu B, Yachida S, Morgan R, et al., Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol 2012; 138: 356-366.
8. Rajagopalan H, Bardelli A, Lengauer C, et al., Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
9. Pao W, Girard N,. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-80.
10. Grisham RN, Iyer G, Garg K, et al., BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119: 548-54.
11. Cohen Y, Xing M, Mambo E, et al., BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-7.
12. Kimura ET, Nikiforova MN, Zhu Z, et al., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
13. Soares P, Trovisco V, Rocha AS, et al., BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-80.
14. Trovisco V, Soares P, Preto A, et al., Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005; 446: 589-95.
15. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-62.
16. Xing M,. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
17. Handkiewicz-Junak D, Czarniecka A, Jarzab B,. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 2010; 322: 8-28.
18. Nikiforov YE, Nikiforova MN,. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-80.
19. Xing M, Tufano RP, Tufaro AP, et al., Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004; 89: 2867-72.
20. Marchetti I, Lessi F, Mazzanti CM, et al., A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009; 19: 837-42.
21. Kim SW, Lee JI, Kim JW, et al., BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010; 95: 3693-700.
22. Nikiforov YE, Ohori NP, Hodak SP, et al., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-7.
23. Li C, Lee KC, Schneider EB, et al., BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012; 97: 4559-70.
24. Dhillon AS, Hagan S, Rath O, et al., MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90.
25. Knauf JA, Ma X, Smith EP, et al., Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65: 4238-45.
26. Franco AT, Malaguarnera R, Refetoff S, et al., Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 2011; 108: 1615-20.
27. Chakravarty D, Santos E, Ryder M, et al., Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121: 4700-11.
28. Guerra A, Sapio MR, Marotta V, et al., The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 517-24.
29. Guerra A, Fugazzola L, Marotta V, et al., A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012; 97: 2333-40.
30. Gandolfi G, Sancisi V, Torricelli F, et al., Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 2013; 98: 934-42.
31. De Biase D, Cesari V, Visani M, et al., High sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J Clin Endocrinol Metab 2014; doi:29:jc20134389.
32. Baldus SE, Schaefer KL, Engers R, et al., Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-9.
33. Wilmott JS, Tembe V, Howle JR, et al., Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012; 11: 2704-08.
34. Yancovitz M, Litterman A, Yoon J, et al., Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 2012; 7: e29336.
35. Nikiforova MN, Wald AI, Roy S, et al., Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013; 98: E1852-60.
36. Capper D, Preusser M, Habel A, et al., Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
37. Ghossein RA, Katabi N, Fagin JA,. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 2013; 98: E1414-21.
38. Ugolini C, Giannini R, Lupi C, et al., Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007; 17: 381-8.
39. Virk RK, van Dyke AL, Finkelstein A, et al., BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 2013; 26: 62-70.
40. Zheng X, Wei S, Han Y, et al., Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 2013; 20: 2266-73.
41. Trovisco V, Couto JP, Cameselle-Teijeiro J, et al., Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol 2008; 69: 683-5.
42. Vasko V, Hu S, Wu G, et al., High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 2005; 90: 5265-9.
43. Dankort D, Filenova E, Collado M, et al., A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007; 21: 379-84.
44. Dankort D, Curley DP, Cartlidge RA, et al., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-52.
45. Shimamura M, Nakahara M, Orim F, et al., Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma. Endocrinology 2013; 154: 4423-30.
46. Cameselle-Teijeiro J, Abdulkader I, Pérez-Becerra R, et al., BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion? Hum Pathol 2009; 40: 1029-35.
47. Namba H, Nakashima M, Hayashi T, et al., Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-7.
48. Nikiforova MN, Kimura ET, Gandhi M, et al., BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-404.
49. Kim KH, Kang DW, Kim SH, et al., Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818-21.
50. Xing M, Westra WH, Tufano RP, et al., BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-9.
51. Kim J, Giuliano AE, Turner RR, et al., Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006; 244: 799-804.
52. Kim TY, Kim WB, Rhee YS, et al., The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-8.
53. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas M, et al., The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-69.
54. Rodolico V, Cabibi D, Pizzolanti G, et al., BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid
55. Lupi C, Giannini R, Ugolini C, et al., Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-90.
56. Kebebew E, Weng J, Bauer J, et al., The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-70.
57. Elisei R, Viola D, Torregrossa L, et al., The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012; 97: 4390-8.
58. Fugazzola L, Puxeddu E, Avenia N, et al., Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455-64.
59. Elisei R, Molinaro E, Agate L, et al., Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010; 95: 1516-27.
60. Fugazzola L, Mannavola D, Cirello V, et al., BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61: 239-43.
61. Puxeddu E, Moretti S, Elisei R, et al., BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414-20.
62. Kim TY, Kim WB, Song JY, et al., The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588-93.
63. Liu RT, Chen YJ, Chou FF, et al., No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-6.
64. Sapio MR, Posca D, Troncone G, et al., Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006; 154: 341-8.
65. Gouveia C, Can NT, Bostrom A, et al., Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-7.
66. Lee JH, Lee ES, Kim YS,. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110: 38-46.
67. Tufano RP, Teixeira GV, Bishop J, et al., BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 2012; 91: 274-86.
68. Kim TH, Park YJ, Lim JA, et al., The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-73.
69. Trovisco V, Soares P, Sobrinho-Simões M,. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006; 37: 781-6.
70. Elisei R, Ugolini C, Viola D, et al., BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-9.
71. Joo JY, Park JY, Yoon YH, et al., Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 2012; 97: 3996-4003.
72. Lim JY, Hong SW, Lee YS, et al., Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013; 23: 1423-30.
73. Barbaro D, Incensati RM, Materazzi G, et al., The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 2014; 45: 462-8.
74. Li C, Aragon Han P, Lee KC, et al., Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab 2013; 98: 3702-12.
75. Xing M, Alzahrani AS, Carson KA, et al., Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-501.
76. Sancisi V, Nicoli D, Ragazzi M, et al., BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012; 97: E1745-9.
77. Ito Y, Yoshida H, Maruo R, et al., BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56: 89-97.
78. Costa AM, Herrero A, Fresno MF, et al., BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol 2008; 68: 618-34.
79. Ito Y, Yoshida H, Kihara M, et al., BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg 2014; 38: 679-87.
80. Sarne DH,. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 2012; 97: 3094-6.
81. Cappola AR, Mandel SJ,. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 2013; 309: 1529-30.
82. Frattini M, Ferrario C, Bressan P, et al., Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436-40.
83. Cheng S, Serra S, Mercado M, et al., A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 2011; 17: 2385-94.
84. Giordano TJ, Kuick R, Thomas DG, et al., Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-56.
85. Jo YS, Li S, Song JH, et al., Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 3667-70.
86. Nucera C, Porrello A, Antonello ZA, et al., B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010; 107: 10649-54.
87. Eloy C, Santos J, Cameselle-Teijeiro J, et al., TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 2012; 460: 587-600.
88. Chou CK, Yang KD, Chou FF, et al., Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013; 98: E196-205.
89. Silva AL, Carmo F, Bugalho MJ,. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Eur J Endocrinol 2013; 168: 795-804.
90. Ulisse S, Baldini E, Sorrenti S, et al., In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 2012; 77: 780-6.
91. Vinagre J, Almeida A, Põpulo H, et al., Frequency of TERT promoter mutations in human cancers. Nat Commun 2013; 4: 2185.
92. Melo M, Rocha AG, Vinagre J, et al., TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014; 99: E754-65.
93. Landa I, Ganly I, Chan TA, et al., Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013; 98: E1562-6.
94. Liu X, Qu S, Liu R, et al., TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014; doi: 10.1210/jc.2013-4048.
95. Salerno P, De Falco V, Tamburrino A, et al., Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010; 95: 450-5.
96. Xing J, Liu R, Xing M, et al., The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 2011; 404: 958-62.
97. Joseph EW, Pratilas CA, Poulikakos PI, et al., The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107: 14903-8.
98. Bollag G, Tsai J, Zhang J, et al., Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11: 873-86.
99. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
100. Prahallad A, Sun C, Huang S, et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
101. Corcoran RB, Ebi H, Turke AB, et al., EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
102. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al., Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3: 520-33.
103. Nathanson KL, Martin AM, Wubbenhorst B, et al., Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013; 19: 4868-78.
104. Jin N, Jiang T, Rosen DM, et al., Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 2011; 17: 6482-9.
105. Mao M, Tian F, Mariadason JM, et al., Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-67.
106. Zuo H, Nakamura Y, Yasuoka H, et al., Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 2007; 57: 12-20.
107. Faustino A, Couto JP, Põpulo H, et al., mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: E1139-49.
108. Mian C, Barollo S, Pennelli G, et al., Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol 2008; 68: 108-16.
109. Barollo S, Pennelli G, Vianello F, et al., BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 2010; 163: 659-63.
110. Ho AL, Grewal RK, Leboeuf R, et al., Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623-32.
111. Davies L, Welch HG,. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 2010; 136: 440-4.